Oncolytics Biotech Inc. Files 6-K Update
Ticker: ONCY · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1129928
Sentiment: neutral
Topics: corporate-update, special-meeting, foreign-private-issuer
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH INC (ONCY) filed a 6-K update on Nov 20, 2025, regarding a special meeting.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on November 20, 2025, reporting as a foreign private issuer. The filing provides an update related to a special meeting. The company's principal executive offices are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121.
Why It Matters
This filing indicates ongoing corporate activities and updates for Oncolytics Biotech Inc. shareholders, potentially related to governance or strategic decisions discussed at a special meeting.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain significant financial or operational news that would immediately impact risk.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Filer of the 6-K
- November 20, 2025 (date) — Filing date
- 4350 Executive Drive, Suite 325 San Diego, CA 92121 (address) — Principal executive offices
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed for the month of November 2025, providing an update related to a special meeting.
What is the filing date of this document?
The filing date is November 20, 2025.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
The principal executive offices are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121.
Does Oncolytics Biotech Inc. file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files annual reports under cover of Form 20-F.
Is this filing being submitted in paper format?
The filing does not indicate submission in paper format under Regulation S-T Rule 101(b)(1).
Filing Stats: 332 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2025-11-20 16:06:56
Filing Documents
- form6kspecialmeetingupdate.htm (6-K) — 17KB
- specialmtgupdate.htm (EX-99.1) — 10KB
- 0001129928-25-000093.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date November 20, 2025 Kirk Look Chief Financial Officer